Universal Registration Document

Overview

The report describes GenSight Biologics' sustained five-year clinical results for LUMEVOQ®, including favorable safety and visual-acuity outcomes. It also records compassionate and expanded-access authorizations in France, Israel and the United States. Manufacturing process transfer to Catalent and multiple 2025 financing transactions supported continued development, although the Group reports insufficient resources to cover the next twelve months of operations.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 14 April 2026
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services